MutT Homolog 1 as a Novel Mediator of RAS Oncogene-Induced Pro-Malignant Pathways
MutT 同源物 1 作为 RAS 癌基因诱导的恶性途径的新型介体
基本信息
- 批准号:9249509
- 负责人:
- 金额:$ 31.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-05-01 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:8-oxo-dGTPAddressAdenocarcinomaAffectAgarAnimal ModelAnimalsBreast Cancer CellBreast Cancer cell lineBreast Epithelial CellsCell AgingCell DeathCell LineCell ProliferationCellsCharacteristicsChronicDNADNA DamageDataDevelopmentDiseaseDrug TargetingEffector CellEpithelialEpithelial CellsEvaluationGenderGoalsHRAS geneHomologous GeneHumanKRAS2 geneLaboratoriesLeadLungLung NeoplasmsMaintenanceMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMediatingMediator of activation proteinMesenchymalMolecularMorphologyMutationNormal CellNormal tissue morphologyOncogenesOncogenicOutcomeOxidation-ReductionOxidative StressPathway interactionsPharmaceutical PreparationsProcessProductionProteinsPublishingReactive Oxygen SpeciesRegulatory PathwayReportingResearchResistanceRoleSignal TransductionStaining methodStainsStressStructure of parenchyma of lungTP53 geneTestingTissuesTreatment EfficacyTumor Cell LineTumor TissueTumorigenicityUp-RegulationValidationWorkbasecell transformationcell typedGTPasediagnostic biomarkerhuman datain vivoinnovationknockout animallung Carcinomamelanocytemouse modelmutantneoplastic cellnovelnovel markeroutcome forecastoverexpressionoxidative DNA damagepre-clinicalpreventprognosticpublic health relevanceras Oncogeneresponsetherapeutic targettherapy outcometraittumortumor xenografttumorigenesistumorigenic
项目摘要
DESCRIPTION (provided by applicant): Approximately 25% of all tumor types sustain oncogenic RAS mutations. Oncogenic RAS activation confers multiple tumor-promoting characteristics including unrestrained proliferation, survival signaling, and increased invasiveness. These features are mediated by oncogene-induced reactive oxygen species (ROS). However oncogenic ROS also lead to DNA damage, which is a major effector of cell death and cell senescence, two common therapeutic outcomes. Hence, RAS-transformed cells must evade ROS- associated damaging effects without entirely eliminating ROS production. Studies have shown that proteins that can effectively suppress ROS-associated anti-tumorigenic functions promote RAS-mediated tumor formation. The mammalian 8-oxo-dGTP triphosphatase, human MutT Homolog 1(MTH1) is unique in that its functionality inhibits oxidative DNA damage but does not directly affect ROS levels. Studies from our laboratory as well as others indicate unusually high expression of MTH1 in cancers associated with activating RAS mutations. Our published and preliminary data further show that oncogenic RAS expression upregulates MTH1 protein levels in a number of different cell types. We also recently reported MTH1 overexpression in normal cells prevents oncogenic RAS-induced oxidative DNA damage and cellular senescence, a critical barrier against oncogene-induced tumorigenesis. Conversely, we found MTH1 suppression selectively affects proliferation and survival pathways in the RAS-transformed counterparts in isogenic breast cancer cell lines. Our preliminary data further indicate that MTH1 suppression affects transformation efficiency, xenograft tumor formation, pro-survival pathways and invasive morphology in oncogenic RAS-transformed cells. Thus our central hypothesis is that elevated MTH1 expression is a critical adaptive change that functionally uncouples the tumor-promoting effects of oncogenic ROS from their damaging effects, thus enhancing proliferation and survival of RAS-transformed cells. The overall goal of this proposal is: 1) to fully characterize the molecular and cellular implications of MTH1 upregulation on oncogenic RAS-induced mechanisms of tumor development and promotion, and 2) to assess the in vivo effects of abrogating MTH1 function in an activated KRAS mouse model of lung cancer. Our studies will provide mechanistic validation for targeting MTH1 in RAS-transformed tumors as a means to enhance therapeutic efficacy by shifting cellular response away from pro-proliferative and pro-survival mechanisms and towards cell senescence or cell death.
描述(由申请人提供):所有肿瘤类型中约25%存在致癌RAS突变。致癌性RAS激活赋予多种肿瘤促进特征,包括不受限制的增殖、存活信号传导和增加的侵袭性。这些特征由癌基因诱导的活性氧(ROS)介导。然而,致癌ROS也导致DNA损伤,这是细胞死亡和细胞衰老的主要效应子,这是两种常见的治疗结果。因此,RAS转化的细胞必须避免ROS相关的损伤作用,而不完全消除ROS的产生。研究表明,能够有效抑制ROS相关的抗肿瘤功能的蛋白质促进RAS介导的肿瘤形成。 哺乳动物8-oxo-dGTP三磷酸酶,人类MutT同系物1(MTH 1)的独特之处在于其功能抑制氧化DNA损伤,但不直接影响ROS水平。我们实验室和其他实验室的研究表明,MTH 1在与激活RAS突变相关的癌症中异常高表达。我们发表的和初步的数据进一步表明,致癌RAS表达上调MTH 1蛋白水平在许多不同的细胞类型。我们最近还报道了MTH 1在正常细胞中的过表达可以防止致癌RAS诱导的氧化DNA损伤和细胞衰老,这是对抗癌基因诱导的肿瘤发生的关键屏障。相反,我们发现MTH 1抑制选择性地影响同基因乳腺癌细胞系中RAS转化对应物的增殖和存活途径。我们的初步数据进一步表明,MTH 1抑制影响转化效率,异种移植肿瘤形成,促生存途径和致癌RAS转化细胞的侵袭性形态。因此,我们的中心假设是,MTH 1表达升高是一个关键的适应性变化,从功能上解偶联致癌活性氧的肿瘤促进作用,从他们的破坏作用,从而提高RAS转化细胞的增殖和生存。 该提案的总体目标是:1)充分表征MTH 1上调对致癌RAS诱导的肿瘤发展和促进机制的分子和细胞影响,以及2)评估在活化的KRAS肺癌小鼠模型中废除MTH 1功能的体内作用。我们的研究将为RAS转化肿瘤中靶向MTH 1提供机制验证,作为通过将细胞反应从促增殖和促存活机制转移到细胞衰老或细胞死亡来增强治疗功效的手段。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Priyamvada Rai其他文献
Priyamvada Rai的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Priyamvada Rai', 18)}}的其他基金
Comprehensive Research Experiences to Advance Training and Education (CREATE) for Future Cancer Researchers
全面的研究经验可促进未来癌症研究人员的培训和教育 (CREATE)
- 批准号:
10269302 - 财政年份:2021
- 资助金额:
$ 31.85万 - 项目类别:
Comprehensive Research Experiences to Advance Training and Education (CREATE) for Future Cancer Researchers
全面的研究经验可促进未来癌症研究人员的培训和教育 (CREATE)
- 批准号:
10458769 - 财政年份:2021
- 资助金额:
$ 31.85万 - 项目类别:
Comprehensive Research Experiences to Advance Training and Education (CREATE) for Future Cancer Researchers
全面的研究经验可促进未来癌症研究人员的培训和教育 (CREATE)
- 批准号:
10664861 - 财政年份:2021
- 资助金额:
$ 31.85万 - 项目类别:
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
去势抵抗性前列腺癌发生和进展的 ROS/RNS 信号传导新机制
- 批准号:
10450017 - 财政年份:2020
- 资助金额:
$ 31.85万 - 项目类别:
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
去势抵抗性前列腺癌发生和进展的 ROS/RNS 信号传导新机制
- 批准号:
10381045 - 财政年份:2020
- 资助金额:
$ 31.85万 - 项目类别:
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
去势抵抗性前列腺癌发生和进展的 ROS/RNS 信号传导新机制
- 批准号:
10524189 - 财政年份:2020
- 资助金额:
$ 31.85万 - 项目类别:
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
去势抵抗性前列腺癌发生和进展的 ROS/RNS 信号传导新机制
- 批准号:
10212358 - 财政年份:2020
- 资助金额:
$ 31.85万 - 项目类别:
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
去势抵抗性前列腺癌发生和进展的 ROS/RNS 信号传导新机制
- 批准号:
10647688 - 财政年份:2020
- 资助金额:
$ 31.85万 - 项目类别:
Novel Mechanisms of ROS/RNS Signaling Underlying Castration-Resistant Prostate Cancer Emergence and Progression
去势抵抗性前列腺癌发生和进展的 ROS/RNS 信号传导新机制
- 批准号:
10737798 - 财政年份:2020
- 资助金额:
$ 31.85万 - 项目类别:
MutT Homolog 1 as a Novel Mediator of RAS Oncogene-Induced Pro-Malignant Pathways
MutT 同源物 1 作为 RAS 癌基因诱导的恶性途径的新型介体
- 批准号:
8481679 - 财政年份:2013
- 资助金额:
$ 31.85万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 31.85万 - 项目类别:
Research Grant